Keyphrases
High Risk
100%
Adaptation
100%
Asthma
100%
Lessons Learned
100%
Omalizumab
100%
Design Rationale
100%
Asthma Severity
25%
Allergen
25%
Risk Factors
12%
Public Health
12%
Pediatric
12%
Ablating
12%
Viral
12%
Viral Infection
12%
High Concentration
12%
Older children
12%
Double-blind Placebo-controlled Trial
12%
Biological Response
12%
Persistent Asthma
12%
IFN Response
12%
Asthma Exacerbation
12%
Early-life Exposure
12%
Antiviral Immune Response
12%
Type 2 Inflammation
12%
Chronic Asthma
12%
Rhinovirus
12%
IgE Antibody
12%
Antigen Exposure
12%
IgE-mediated
12%
IgE Response
12%
Offending
12%
Innate Antiviral
12%
Aeroallergen Sensitization
12%
Immunology and Microbiology
Asthma
100%
Omalizumab
100%
Immunoglobulin E
54%
Allergen
18%
Sensitization
18%
Viral Disease
9%
Asthma Exacerbation
9%
Antiviral Immune Response
9%
Immunoglobulin E Antibody
9%
Rhinovirus
9%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
100%
Omalizumab
100%
Immunoglobulin E
50%
Allergen
16%
Placebo
8%
Inflammation
8%
Antivirus Agent
8%
Virus Infection
8%
Rhinovirus
8%
Immunoglobulin E Antibody
8%